Investor Guide
How to Evaluate Biotech Startups
A structured way to work through an early-stage life sciences pitch, instead of relying on how confident the deck sounds.
Most early-stage biotech pitches are, by design, optimistic. The founder's job is to make the case for their science; the investor's job is to test it. Evaluating a biotech startup well means separating what the data actually shows from what the founder's interpretation adds on top of it — and that gap is usually where the real risk lives.
ChaosBio's own review process, applied to every company it considers, works through four categories of risk in roughly this order: the science itself, whether the team can execute on it, the development path from here to the next milestone, and — where relevant — the manufacturing and regulatory questions that determine whether the science can actually become a product.
Science risk
Is the underlying biology or engineering characterized well enough, with data that supports the claim rather than just gesturing at it?
Execution risk
Is the team coachable, transparent, and self-aware about its own gaps — and does it have a credible plan to fill them?
Development risk
Are the next milestones realistic, fundable on the amount being raised, and meaningful to the investors or acquirers who come after this round?
Manufacturing and regulatory risk
Have the CMC, scale-up, and regulatory questions been addressed early enough to avoid the preventable surprises that stall promising companies?
This is a summary of the framework, not the full version — the complete methodology, with the reasoning behind each category, is in ChaosBio's investment thesis. For sector-specific versions of this framework, see the Investment Themes pages.
See this framework applied to real deals.
ChaosBio's Investor Network shares opportunities that have already been reviewed against this framework, with the reasoning included in the memo.